Virginia Velasco-Tirado1,2,3, Angela Romero-Alegria2,4,5, Javier Pardo-Lledías6,7, Montserrat Alonso-Sardón2,3,4, Amparo Lopez-Bernus2,4,8, Jose Quiñones Sampedro2,9, Luis Muñoz Bellvis2,9, Alicia Iglesias Gomez2,4,8, Antonio Muro2,4,10, Juan Luis Muñoz Bellido2,4,11,12, Manuel Iglesias-Iglesias2,9, Marcelo Fernando Jimenez Lopez2,13, Moncef Belhassen-García2,4,8. 1. Servicio de Dermatología, Complejo Asistencial Universitario de Salamanca (CAUSA), Paseo de San Vicente 58-182, Salamanca. 2. Instituto de Investigación Biomédica de Salamanca (IBSAL), CAUSA, Hospital Virgen de la Vega 10° planta, Paseo de San Vicente 58-182, Salamanca. 3. Área de Medicina Preventiva y Salud Pública, Universidad de Salamanca, Facultad de Medicina, Campus Miguel de Unamuno s/n, Salamanca. 4. Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Universidad de Salamanca, Facultad de Farmacia, Area de Parasitología, Campus Miguel de Unamuno s/n, Salamanca. 5. Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca (CAUSA), Paseo de San Vicente 58-182, Salamanca. 6. Servicio de Medicina Interna, Hospital General de Palencia 'Río Carrión', C/Donantes de Sangre s/n., Palencia. 7. Servicio de Medicina Interna. Hospital Marqués de Valdecilla. Avenida Vadecilla 25, Santander. 8. Servicio de Medicina Interna, Sección de Enfermedades Infecciosas, CAUSA, Paseo de San Vicente 58-182, Salamanca. 9. Servicio de Cirugía, Complejo Asistencial Universitario de Salamanca (CAUSA) Paseo de San Vicente 58-182, Salamanca. 10. Laboratorio de Inmunología Parasitaria y Molecular, Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno s/n, Salamanca. 11. Servicio de Microbiología, CAUSA, Paseo de San Vicente 58-182, Salamanca. 12. Grupo de Investigacion Reconocido MICRAPE, Departamento de Ciencias Biomedicas y del Diagnostico, Universidad de Salamanca, Campus Miguel de Unamuno s/n, Salamanca. 13. Servicio de Cirugía Toracica, Complejo Asistencial Universitario de Salamanca (CAUSA) Paseo de San Vicente 58-182, Salamanca, Spain.
Abstract
Background: Management options for cystic echinococcosis (CE) remain a serious problem. The main aim of this study was to examine the selection and complications of treatment applied in patients with CE. The second aim was to evaluate the mortality rate and causative factors. Methods: A retrospective descriptive study of patients diagnosed with CE between 1998 and 2015 was conducted, according to ICD-9 (code 122·0 to 122·9) criteria in the Complejo Asistencial Universitario of Salamanca, Spain. Results: Four-hundred-ninety-one (491) patients were diagnosed with CE disease and the treatment applied in these patients were: 166 (33.8%) patients received only surgery, 176 (35.8%) surgery and drugs, 17 (3.5%) drugs alone, in 131 (26.7%) patients the strategy was 'watch and wait', and only one patient (0.2%) was applied puncture-aspiration-injection-respiration (PAIR). Thus, a total of 342 patients received surgery, either alone (166) or combined with drugs (176), and a total of 193 (39.4%) patients were medically treated, either alone (17) or combined with surgery (176); 123 (63.7%) patients used albendazole alone; and 70 (36.3%) patients used a combination of albendazole and praziquantel. Sixty-five patients (19.0%) had complications after surgery and seven of them (2%) died. Only 15 (7.8%) cases had side effects from anthelmintics. Throughout the study period, 80 (16.3%) patients died, 14 (2.9%) of them due to CE disease. Conclusions: Complications of CE are one of the most common causes of mortality in CE patients, with size, location, and number of cysts, and the 'watch and wait' treatment strategy being the main factors associated with mortality.
Background: Management options for cystic echinococcosis (CE) remain a serious problem. The main aim of this study was to examine the selection and complications of treatment applied in patients with CE. The second aim was to evaluate the mortality rate and causative factors. Methods: A retrospective descriptive study of patients diagnosed with CE between 1998 and 2015 was conducted, according to ICD-9 (code 122·0 to 122·9) criteria in the Complejo Asistencial Universitario of Salamanca, Spain. Results: Four-hundred-ninety-one (491) patients were diagnosed with CE disease and the treatment applied in these patients were: 166 (33.8%) patients received only surgery, 176 (35.8%) surgery and drugs, 17 (3.5%) drugs alone, in 131 (26.7%) patients the strategy was 'watch and wait', and only one patient (0.2%) was applied puncture-aspiration-injection-respiration (PAIR). Thus, a total of 342 patients received surgery, either alone (166) or combined with drugs (176), and a total of 193 (39.4%) patients were medically treated, either alone (17) or combined with surgery (176); 123 (63.7%) patients used albendazole alone; and 70 (36.3%) patients used a combination of albendazole and praziquantel. Sixty-five patients (19.0%) had complications after surgery and seven of them (2%) died. Only 15 (7.8%) cases had side effects from anthelmintics. Throughout the study period, 80 (16.3%) patients died, 14 (2.9%) of them due to CE disease. Conclusions: Complications of CE are one of the most common causes of mortality in CE patients, with size, location, and number of cysts, and the 'watch and wait' treatment strategy being the main factors associated with mortality.
Authors: Javier Collado-Aliaga; Ángela Romero-Alegría; Montserrat Alonso-Sardón; Antonio Muro; Amparo López-Bernus; Virginia Velasco-Tirado; Juan Luis Muñoz Bellido; Javier Pardo-Lledias; Moncef Belhassen-García Journal: Am J Trop Med Hyg Date: 2019-09 Impact factor: 2.345
Authors: Fernando Salvador; Eva Calabuig; Rogelio López-Vélez; Javier Pardo-Lledías; Diego Torrús; María Peñaranda; Azucena Rodríguez-Guardado; Milagros García López-Hortelano; Moncef Belhassen-García Journal: Am J Trop Med Hyg Date: 2020-05-07 Impact factor: 2.345
Authors: Javier Collado Aliaga; Ángela Romero-Alegría; Montserrat Alonso-Sardón; Vanessa Prieto-Vicente; Amparo López-Bernus; Virginia Velasco-Tirado; Celia Sendra de la Ossa; Javier Pardo-Lledias; Moncef Belhassen-García Journal: Am J Trop Med Hyg Date: 2021-07-19 Impact factor: 3.707
Authors: Moncef Belhassen-García; Montserrat Alonso-Sardón; Antonio Muro; Juan Luis Muñoz Bellido; Javier Pardo-Lledias Journal: Am J Trop Med Hyg Date: 2020-01 Impact factor: 2.345